Research Article

Effects of hsa-miR-28-5p on Adriamycin Sensitivity in Diffuse Large B-Cell Lymphoma

Shufang Yan, Qinyu Shang, Haipeng Zhu, Ken Chen, Xinxia Li, Hongliang Gao, Bo Liu, Mei Feng, and Lixia Gao

1Department of Critical Care Medicine, Karamay Central Hospital, Karamay City 834000, The Xinjiang Uygur Autonomous Region of China, China
2Department of Pathology, The Tumor Hospital Affiliated to Xinjiang Medical University, No. 789 Suzhou Dongjie, Urumqi 830011, The Xinjiang Uygur Autonomous Region of China, China
3Xinjiang Medical University, No. 567 North Shangde Road, Urumqi 830011, The Xinjiang Uygur Autonomous Region of China, China
4Department of Hematology Oncology of Karamay Central Hospital, Number 67, Junggar Road, Karamay Region, Karamay 834000, The Xinjiang Uygur Autonomous Region of China, China
5Department of Pathology, The First Affiliated Hospital of Xinjiang Medical University, No. 137 Liyushan Southern Road, Urumqi 830054, The Xinjiang Uygur Autonomous Region of China, China
6Department of Emergency of Karamay Central Hospital, Number 67, Junggar Road, Karamay Region, Karamay 834000, The Xinjiang Uygur Autonomous Region of China, China

Correspondence should be addressed to Shufang Yan; ysf.1983@163.com

Received 7 May 2022; Revised 20 June 2022; Accepted 24 June 2022; Published 13 July 2022

Academic Editor: Qing Li

Copyright © 2022 Shufang Yan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Adriamycin (doxorubicin) is an important traditional drug that exhibits cytotoxicity in Diffuse Large B-cell Lymphoma (DLBCL). Doxorubicin affects the DLBCL cells at all stages of their cell cycle. Combined with our previous results, this study discovered that the overexpression of hsa-miR-28-5p inhibited the proliferation, promoted apoptosis, and triggered cell cycle arrest at the S-phase in DLBCL cells. However, the effect of (Homo sapiens, hsa)-microRNA (miR)-28-5p on doxorubicin sensitivity in DLBCL has not been investigated. This study aims to reveal the effects of hsa-miR-28-5p on doxorubicin sensitivity at the level of DLBCL cells.

Methods. To determine the optimal concentration of doxorubicin, different concentrations of doxorubicin were used to treat DLBCL cells. CCK-8 assay was used to detect the proliferation of DLBCL cells. hsa-miR-28-5p mimic NC and hsa-miR-28-5p mimic were transfected to doxorubicin-mediated DLBCL cells. Simultaneously, blank control groups were set up. The cells were cultured and transfected for 24 h. Next, each group was administered with different concentrations of doxorubicin and cultured again for 24 h to observe the effects of hsa-miR-28-5p on doxorubicin sensitivity. hsa-miR-28-5p mimic + doxorubicin remarkably decreased proliferation of DLBCL. Cell apoptosis rate was the highest in hsa-miR-28-5p mimic + doxorubicin group. Apart from that, hsa-miR-28-5p mimic plus doxorubicin had the best effect in promoting DLBCL cell apoptosis. After the intervention of hsa-miR-28-5p mimic + doxorubicin on DLBCL cells, the cell cycle was arrested in the S-phase and DNA synthesis was blocked.

Results. The optimal concentration of doxorubicin targeting DLBCL cells was found to be 3.028 μmol/l. The effect of doxorubicin on DLBCL cells was time- and concentration-dependent. hsa-miR-28-5p mimic + doxorubicin remarkably decreased proliferation of DLBCL. DLBCL cell apoptosis rate was the highest in hsa-miR-28-5p mimic + doxorubicin group. Apart from that, hsa-miR-28-5p mimic plus doxorubicin had the best effect in promoting DLBCL cell apoptosis. After the intervention of hsa-miR-28-5p mimic + doxorubicin on DLBCL cells, the cell cycle was arrested in the S-phase and DNA synthesis was blocked. hsa-miR-28-5p mimic + doxorubicin could regulate the cycle of DLBCL cells. As a result, overexpression of hsa-miR-28-5p combined with doxorubicin is possibly involved in the development of DLBCL by affecting the proliferation, apoptosis, and cycle of DLBCL cells.

Conclusion. Combining with the literature, this suggested hsa-miR-28-5p may influence DLBCL occurrence and therapeutic effect by regulating the PD-L1 level.
miR-28-5p mimic and doxorubicin may be considered more effective in inhibiting growth, arresting the cell cycle, and promoting cell apoptosis of DLBCL cells compared to using doxorubicin alone. The effects of doxorubicin on DLBCL cells were found to be time- and concentration-dependent. The overexpression of has-miR-28-5p enhanced the effect of doxorubicin on DLBCL cells, which may be attributed to the regulation of PD-L1 levels.

1. Introduction

Diffuse large B-cell lymphoma (DLBCL) refers to the most common pathological subtype of non-Hodgkin’s lymphoma (NHL) and is the most common type of adult lymphoma, occupying 33.27% [1]. Although regarded as an independent disease by the World Health Organization, DLBCL exhibits great heterogeneity in its clinical features, morphological features, genetic features, immunophenotype, curative effect, long-term prognosis, and so on [1]. Currently, R-CHOP is considered the standard therapy for DLBCL, which includes rituximab (R)-cyclosphosphamide (C) + adriamycin (doxorubicin hydrochloride, H) + vincristine (Oncovin, VCR, O) + prednisone (P). The continuous progress of modern radiotherapy, chemotherapy, immunotherapy, and targeted therapy has not only ameliorated the quality of life and the long-term prognosis of DLBCL patients but also has prolonged the progression-free survival and overall survival (OS) rates of such patients. However, due to the individualized difference in the treatment of DLBCL patients and the drug resistance of tumor cells under the constant stimulation of chemotherapy drugs, one-third of patients often relapse and enter the stage of tumor progression shortly after the treatment [2]. In China, the incidence of lymphoma is relatively high, but the OS status is low. Therefore, studying the mechanism of drug resistance in DLBCL can further improve the current treatment method of DLBCL, as well as supply theoretical support to the development of new drugs to extend the OS of lymphoma patients in China. Overall, there is a need to urgently settle the survival of refractory (R/R) DLBCL.

Our research group showed that the overexpression of Homo sapiens (hsa)-microRNA (miR)-28-5p inhibited the proliferation, promoted apoptosis, and arrested the cycle of DLBCL cells in the S-phase [3]. However, the effect of hsa-miR-28-5p on the sensitivity of doxorubicin in DLBCL remains unclear.

2. Material and Methods

2.1. Cells and Culture. Human DLBCL cells: we chose the OCI-LY1 cell line (GCB) in the Institute of Jennio Biosciences (CBP60265, Guangzhou, China) and cultured them within RPMI-1640 medium (C11875000CP/8119428, Gibco, USA) that contained 1% penicillin-streptomycin (PS) (15070-063, 10000U, GIBCO, USA) as well as 10% fetal bovine serum (FBS) (FND500, Excell Bio, USA). All cells were incubated at 37°C in a humidified incubator with 5% CO₂.

2.2. Cell Transfection. The hsa-miR-28-5p mimic (26660, Suzhou, China) and hsa-miR-28-5p mimic negative control (NC) (05215, Suzhou, China) were obtained from Gene Pharma. Lipofectamine 3000® (L3000-008, Invitrogen, USA) was adopted for transfecting the cells as per the manufacturer’s instructions. The NC and hsa-miR-28-5p mimics were labeled with red fluorescence (0.1 μm) and then transfected into the cells and incubated for 48 h post-transfection. Red fluorescence intensity was observed with naked eyes with the fluorescence microscope to determine the transfection efficiency, which was determined to be more than 70%.

2.3. Cell Counting Kit-8 (CCK-8). Cell proliferation was practiced with the use of the CCK-8 reagent (N20821, FC101-03, Beijing, China). Seed OCI-LY1 cells into 96-well plates at the density of 5 × 10³ cells/well. According to the incubation period, this work added CCK-8 solution (10 μL) to culture OCI-LY1 cells under 37°C for a 1 h period. The microplate reader was then adopted for measuring absorbance (OD) value at 450 nm.

2.4. Soft Agar Colony-Forming Assay. OCI-LY1 cells were grown in the indicated conditions. We plated cells in 6-well plates (1.5 mL/well) and cultivated them for a month. Meanwhile, 300 μL of culture medium was added to the plates every three days to avoid drying. Also, the level of cell clone formation was constantly monitored under a microscope. After about a month, the cells were washed with PBS (ZLI-9062, Beijing, China), and the colonies were stained using crystal violet (0.005%, Shanghai, China). The number of cells from each group was compared and analyzed, and the rate of clone formation was calculated. Later, twenty fields of vision were randomly selected and observed under an inverted microscope (100×). The clone formation rate was calculated as the ratio of the number of > 50 clones divided by all clones in the fields of vision scored under a microscope.

2.5. Mitochondrial Membrane Potential Assay. Flow cytometry was adopted for detecting mitochondrial membrane potential. Cells were collected and transferred to a centrifuge tube, the mixture was centrifuged at 1000 rpm for 5 min, and then the supernatant was discarded. OCI-LY1 cells were washed twice with cold PBS, and the supernatant was removed. Rhodamine 123 (83702, sigma, USA) with a volume of 500 μL was taken to resuspend these cells with a final concentration of 10 μM. The cells were incubated in an incubator at 37°C for 30 min, washed, and resuspended with PBS. In addition, the fluorescence intensity was measured at the excitation wavelength of 488 nm and the emission wavelength of 529 nm by the flow cytometry, respectively. Finally, FlowJo cytometry analysis software was adopted to
analyze early apoptosis in cells of different groups. Meanwhile, it was necessary to ensure the consistency of the pH value in the balanced dye solution during the experiment.

2.6. Caspase-3 Activity Assay. The cells were collected in a tube and centrifuged. After centrifugation, the supernatant was discarded and 100 μL of reagent II was supplemented to the pellet based on the number of cells (about 10⁶). The visible spectrophotometer (Nano-100, Hangzhou, China)/Enzyme labeling instrument (xMarkTM, Bio-Rad, USA) was preheated for more than 30 min while the wavelength was adjusted to 405 nm, and the machine was set to zero using distilled water. Next, to prepare the standard curve, the 5 mmol/L PNA reagent was diluted to different concentrations of 200, 100, 50, 25, 12.5, and 0 mmol/L solutions using a standard diluent. Simultaneously, the test sample was also prepared, and the absorbance was measured at 405 nm. The caspase-3 activity was determined with the use of a caspase-3 activity assay kit (BC3830, Beijing, China), following the manufacturer’s instructions.

2.7. Flow Cytometry Assay. Flow cytometry (LSRFortessa, BD, USA) was applied to analyze the cell cycle. We resuspended cells resuspended in 500 μL of PBS (ZLI-9062, Beijing, China). Meanwhile, 3.5 mL of anhydrous ethanol was used for fixation overnight. The suspension was centrifuged for a 5 min period at 2,000 rpm to separate cells (1 × 10⁶). Next, the cells were rinsed twice with precooled PBS, resuspended in 500 μL of PI/RNase Staining Buffer (550825, BD, USA), and passed sequentially through the 200 μm-mesh nylon sieves to obtain a single-cell suspension. This was followed by 30 min incubation in the dark at 4°C. The samples were then measured within one hour of incubation. The difference in the cell cycle among different groups was compared to understand the distribution of cells at different time points. For apoptosis analysis, collect cells after transfection for 48 h. The Annexin V-PE/7-AAD Kit (9283373, 559763, BD, USA) was employed for cell double-staining and tested after half an hour.

2.8. Tissue Samples. The current work was permitted by the Medical Ethics Committees of The Tumor Hospital Affiliated with Xinjiang Medical University and Karamay Central Hospital. We screened 192 patients between January 2010 and December 2021 and finally enrolled 52 patients in the study. All patients were treatment-naive, and each of their samples was fixed in the formalin-fixed paraffin-embedded (FFPE) tissue blocks. Table 1 presents the characteristics of FFPE tissues obtained from 52 cases of our study.

2.8.1. Pathological Data

(1) Immunohistochemistry (IHC). A fully automatic immunohistochemistry instrument was used for the IHC assay. The antibodies selected for paraffin sections were PD-L1 and SP263 (Roche). DLBCL is highly heterogeneous, i.e., different individuals of the same tumor exhibit different biological characteristics. It is worth determining the cutoff value of PD-L1 (programmed death-ligand 1, also called B7-H1 or CD274) systematically. For example, the melanoma patients treated with Nivolumab showed the ORR (overall response rate; CR: complete remission; PR: partial remission) to be 67% in the 5% positive group, but 19% in the PD-L1 negative group. Even though PD-L1 expression was reported to be significantly correlated with ORR [4], the same cutoff value in patients suffering from non-small-cell lung cancer (NSCLC) suggested that PD-L1 expression was not associated with ORR [5]. Since selecting the cutoff value of PD-L1 is controversial, we used the cutoff score as ≥ 5% for PD-L1 in the present study. The positive standards for CD10 (56C6, Gene company, 1: 50, Cytomembrane), Bcl-6 (GI191E/A8, ZSBIO, 1: 80, Nuclei), and MUM-1 (Mum1p, MXBIO, ready to use, Nuclei) were reported to be ≥ 30% [6]. Based on Han’s algorithm, DLBCL was further divided into germinal center B-cell (GC B) subtype displaying the MUM1+, Bcl-6+, CD10− or CD10+ phenotype and the non-GCB subtype exhibiting MUM1+, CD10−, Bcl-6+, or Bcl-6− phenotype (including unclassified and ABC subtype in our study).

2.9. Follow-Up Visits. During diagnosis, the follow-ups were initiated through phone or hospital visits, which lasted till March 29th, 2022. The causes for the termination of the follow-up were also recorded. Overall survival (OS) was deemed as the proportion of the overall number of survivors after the follow-up by the original overall patient numbers. In this study, the original diagnosis was “0,” after which we rated the 1-month survival.
2.10. Statistical Analysis. Data processing was carried out using SPSS 23.0 and GraphPad Prism 8.0 software. All data were represented as means ± S.D. Student’s t-test, one-way ANOVA, and Fisher’s exact test were taken with the purpose of fulfilling statistical analysis. \( P < 0.05 \) was regarded to be of statistical significance.

3. Results

3.1. After Intervention with Different Concentrations of Doxorubicin, the CCK-8 Test Was Used to Detect the Proliferation of DLBCL Cells to Explore the Most Suitable Concentration of Doxorubicin. At the concentration of 8 \( \mu \text{mol/l} \) of doxorubicin, the inhibition rate of OCI-LY1 cell proliferation was found to be 69.312 ± 5.359%, which was significantly higher than the inhibition rates 59.427 ± 4.145%, 39.563 ± 7.350%, 25.340 ± 4.835%, and 17.108 ± 3.957% at 4, 2, 1, and 0.5 \( \mu \text{mol/l} \) concentrations, respectively \( (P < 0.05) \). An increase in the concentration of doxorubicin resulted in a gradual increase in the suppression of the proliferation of OCI-LY1 cells, with significant differences between the groups \( (P < 0.05) \). The IC50 of doxorubicin used to intervene with OCI-LY1 cells was found to be 3.028 \( \mu \text{mol/l} \) for 24 h, which laid a foundation for future experiments. Overall, we found that doxorubicin hindered the proliferation of DLBCL cells, with an increase in the concentration of doxorubicin enhancing the inhibition rate of DLBCL cells (Figures 1 and 2).

3.2. The Effect of hsa-miR-28-5p on Doxorubicin Sensitivity in DLBCL Cells

3.2.1. Impact of Different Intervention Times of hsa-miR-28-5p on Doxorubicin Sensitivity in DLBCL Cells. In our study, the survival rate of OCI-LY1 cells in the hsa-miR-28-5p mimic + doxorubicin group (64.272 ± 2.525%) was found to be the lowest after 24 h, with an appreciable difference from that of the control \( (100 ± 3.163\%) \), doxorubicin \( (76.533 ± 3.064\%) \), and hsa-miR-28-5p mimic NC + doxorubicin groups \( (74.448 ± 1.848\%) \) \( (P < 0.05) \). The cell survival rate of the Control group was different from that of hsa-miR-28-5p mimic NC + doxorubicin and doxorubicin groups, respectively \( (P < 0.05) \), but there existed no obvious difference between doxorubicin group and hsa-miR-28-5p mimic NC + doxorubicin group \( (P > 0.05) \). After 48 h of intervention, the survival rate was lowest in the hsa-miR-28-5p mimic + doxorubicin group \( (39.351 ± 5.9\%) \), with obvious differences between the control \( (100 ± 7.953\%) \) and hsa-miR-28-5p mimic + doxorubicin groups \( (57.478 ± 2.187\%) \) and hsa-miR-28-5p mimic + doxorubicin groups, and also between hsa-miR-28-5p mimic + doxorubicin and hsa-miR-28-5p mimic NC + doxorubicin groups \( (55.039 ± 1.612\%) \) \( (P < 0.05) \). The survival rate of cells in the control group was different from that of the doxorubicin group, and hsa-miR-28-5p mimic NC + doxorubicin group \( (P < 0.05) \), with no obvious difference between doxorubicin and hsa-miR-28-5p mimic NC + doxorubicin groups \( (P > 0.05) \). After 72 h of intervention, the lowest cell survival was observed in the hsa-miR-28-5p mimic + doxorubicin group \( (27.216 ± 1.238\%) \), with an unsubtle difference from that of the control \( (100 ± 3.368\%) \), doxorubicin \( (46.159 ± 2.187\%) \), and hsa-miR-28-5p mimic NC + doxorubicin groups \( (43.250 ± 3.060\%) \) \( (P < 0.05) \). Moreover, clear differences in the cell survival rate were observed between the control and doxorubicin groups, and the control and hsa-miR-28-5p mimic NC + doxorubicin groups \( (P < 0.05) \). However, no differences were found between the doxorubicin and hsa-miR-28-5p mimic NC + doxorubicin groups \( (P > 0.05) \). After 96 h of intervention, the survival rate was observed to be the lowest in the hsa-miR-28-5p mimic + doxorubicin group \( (14.966 ± 1.678\%) \) compared to that of the control \( (100 ± 5.933\%) \), doxorubicin \( (34.592 ± 2.386\%) \), and hsa-miR-28-5p mimic NC + doxorubicin groups \( (33.764 ± 1.645\%) \) \( (P < 0.05) \). The cell survival rate of the control group was different from that of hsa-miR-28-5p mimic NC + doxorubicin and doxorubicin groups, respectively \( (P < 0.05) \), but there was no significant difference between doxorubicin group and hsa-miR-28-5p mimic NC + doxorubicin group \( (P > 0.05) \) (Figure 2). Overall, we found that the survival rate of DLBCL cells showed a gradual decrease with an increase in the intervention time, with the survival rate being the lowest in the hsa-miR-28-5p mimic + doxorubicin group at an identical intervention time (Figures 3 and 4).

3.2.2. Effect of hsa-miR-28-5p on Doxorubicin Sensitivity in DLBCL Cells with Different Intervention Concentrations of Doxorubicin. At the concentration of 8 \( \mu \text{mol/l} \) of doxorubicin, the inhibition rate of OCI-LY1 cells was found to be 69.312 ± 5.358% in the control + doxorubicin group, which was different from the inhibition rates of 59.428 ± 4.147%, 39.562 ± 7.348%, 25.34 ± 4.836%, and 17.108 ± 3.959 at 4, 2, 1, and 0.5 \( \mu \text{mol/L} \) concentrations, respectively, indicating different inhibition rates of cell proliferation by different concentrations \( (P < 0.05) \). Similarly, at the doxorubicin concentration of 8 \( \mu \text{mol/l} \), the inhibition rate in the hsa-miR-28-5p mimic NC + doxorubicin group was 74.614 ± 3.947% compared to 62.454 ± 1.911%, 44.83 ± 3.642%, 26.65 ± 3.610%, and 20.492 ± 2.856% at 4, 2, 1, and 0.5 \( \mu \text{mol/L} \) concentrations, respectively, exhibiting diverse inhibition rates of cell proliferation \( (P < 0.05) \). At the doxorubicin concentration of 8 \( \mu \text{mol/l} \), the inhibition rate in hsa-miR-28-5p mimic + doxorubicin group was 85.554 ± 2.981%, compared to 72.616 ± 5.234%, 64.16 ± 4.378%, 41.216 ± 4.018%, and 29 ± 3.453% at 4, 2, 1, and 0.5 \( \mu \text{mol/L} \) concentrations. Different doxorubicin concentrations showed different cell inhibition rates in the hsa-miR-28-5p mimic + doxorubicin group \( (P < 0.05) \). Thus, we found that with an increase in doxorubicin concentration, the inhibition of DLBCL cell growth became steadily higher (Figures 5 and 6). Also, the hsa-miR-28-5p mimic + doxorubicin group showed the highest inhibition rate on the cell growth of DLBCL at the same intervention concentration of doxorubicin.

3.3. Exploration of the Mechanism Underlying the Effect of hsa-miR-28-5p on Doxorubicin Sensitivity in DLBCL Cells

3.3.1. Soft Agar Colony-Forming Assay. The cell clone formation assay determined that the clone cell number of the OCI-LY1 cells in hsa-miR-28-5p mimic + doxorubicin, hsa-
miR-28-5p mimic NC+doxorubicin, doxorubicin, and control groups were found to be 17.000 ± 5.568, 31.333 ± 5.508, 33.000 ± 5.000, and 71.667 ± 9.452, respectively. The hsa-miR-28-5p mimic+doxorubicin group displayed the least number of cell clones, exhibiting a statistically significant difference from the other groups (P < 0.05). There existed a difference in the number of cell clones between the control group and hsa-miR-28-5p NC+doxorubicin group, and the doxorubicin group, respectively (P < 0.05). The difference in the number of cell clones between hsa-miR-28-5p mimic NC+doxorubicin and doxorubicin groups did not appear (P > 0.05), which indicated that hsa-miR-28-5p mimic could enhance the inhibiting ability of doxorubicin on the proliferation of OCI-LY1 cells. The final result of this experiment demonstrated that the overexpression of hsa-miR-28-5p could improve the ability of doxorubicin with the purpose of inhibiting the proliferation of DLBCL cells (Figures 7 and 8).

3.3.2. Detection of Mitochondrial Membrane Potential Using Flow Cytometry. The fluorescence intensity of Rhodamine 123 in hsa-miR-28-5p mimic + doxorubicin, hsa-miR-28-5p mimic NC + doxorubicin, doxorubicin, and control groups was found to be 48.226 ± 1.633%, 64.652 ± 3.070, 64.054 ± 2.985%, and 100.000 ± 4.356%, respectively. The fluorescence intensity between the group hsa-miR-28-5p mimic+doxorubicin and the remaining three groups showed a statistical difference (P < 0.05). Also, the intensity between the control and hsa-miR-28-5p mimic NC + doxorubicin group, and the control and doxorubicin groups showed statistical differences (P < 0.05). However, no differences were found in the fluorescence intensity between hsa-miR-28-5p mimic NC + doxorubicin and the doxorubicin groups (P > 0.05). The lowest fluorescence activity of Rhodamine 123 was observed in the hsa-miR-28-5p mimic + doxorubicin group. Overall, our
Figure 4: The images of OCI-LY1 cells in different groups at different intervention times (100x).

Figure 5: Images of OCI-LY1 cells in different groups treated with different concentrations of doxorubicin (100x).

Figure 6: The proliferation of OCI-LY1 cells in different groups treated with different concentrations of doxorubicin. *P < 0.05 vs. doxorubicin (0.5 µM) group; #P < 0.05 vs. doxorubicin (1 µM) group; ##P < 0.05 vs. doxorubicin (2 µM) group; ###P < 0.05 vs. doxorubicin (4 µM) group.
results showed that upon using doxorubicin alone, the fluorescence intensity of Rhodamine 123 showed a slight decrease, which also indicated a slight decrease in the mitochondrial membrane potential and mitochondrial membrane integrity. However, the combination of hsa-miR-28-5p mimic and doxorubicin showed an obvious decline in the fluorescence intensity of Rhodamine 123. Thus, the visibly decreased mitochondrial membrane potential in the hsa-miR-28-5p mimic + doxorubicin group implied that the combination of both drugs made the tumor cells present with early apoptosis during the treatment of DLBCL (Figure 9).

3.3.3. Caspase-3 Activity Assay. The caspase-3 activities of the cells in the hsa-miR-28-5p mimic + doxorubicin, hsa-miR-28-5p mimic NC + doxorubicin, doxorubicin, and the control groups were found to be 35.463 ± 6.493, 27.374 ± 2.389, 24.327 ± 3.099, and 14.806 ± 2.145 U/mg protein, respectively, exhibiting a gradually decreasing trend. The caspase-3 activity of the hsa-miR-28-5p mimic + doxorubicin group was obviously different, exhibiting the highest apoptotic cell percentage and most potent anti-DLBCL therapeutic effect compared to the remaining three groups. The activity of caspase-3 in the control group,
Doxorubicin group, hsa-miR-28-5p mimic NC + doxorubicin group, and hsa-miR-28-5p mimic + doxorubicin group increased successively, and the difference of caspase-3 activity between the control group and doxorubicin group, hsa-miR-28-5p mimic NC + doxorubicin and control groups were statistically significant, respectively ($P < 0.05$). It can be seen that doxorubicin enhances DLBCL cell apoptosis. The final results demonstrated that hsa-miR-28-5p mimic could enhance the role of doxorubicin in promoting DLBCL apoptosis (Figure 10).

### 3.3.4. Impact of the Combination of hsa-miR-28-5p Mimic and Doxorubicin on Apoptosis of DLBCL Cells

The apoptosis rate in control group was different from that of the hsa-miR-28-5p mimic NC + doxorubicin and doxorubicin groups. Early apoptosis rate in the hsa-miR-28-5p mimic + doxorubicin group (15.23%) was found to be higher than that of the control (2.68%), doxorubicin (7.02%), and hsa-miR-28-5p mimic NC + doxorubicin groups (6.51%). Overall, our results suggested that the combination of doxorubicin and hsa-miR-28-5p mimic accelerated the apoptosis of DLBCL cells, improving the therapeutic efficacy of doxorubicin (Figure 11).

### 3.3.5. Effects of the Combination of hsa-miR-28-5p Mimic and Doxorubicin on the Cell Cycle of DLBCL Cells

The cell cycle was explored using flow cytometry. We found that the cell cycle was arrested at the S-phase in 38.027 ± 0.488%, 21.617 ± 0.635%, 20.440 ± 0.606%, and 15.897 ± 0.225% of cells in the hsa-miR-28-5p mimic + doxorubicin, hsa-miR-28-5p mimic NC + doxorubicin, doxorubicin, and control groups, respectively. The hsa-miR-28-5p mimic + doxorubicin group showed an increased percentage of cells in the G1 phase.

---

**Figure 9:** Flow and column diagrams of fluorescence detection of Rhodamine 123. *$P < 0.05$ vs. control group; $\#P < 0.05$ vs. doxorubicin group; $\&P < 0.05$ vs. hsa-miR-28-5p mimic NC + doxorubicin group.**

---

**Figure 10:** Flow and column diagrams of fluorescence detection of Rhodamine 123. *$P < 0.05$ vs. control group; $\#P < 0.05$ vs. doxorubicin group; $\&P < 0.05$ vs. hsa-miR-28-5p mimic NC + doxorubicin group.**

---

**Figure 11:** Flow and column diagrams of fluorescence detection of Rhodamine 123. *$P < 0.05$ vs. control group; $\#P < 0.05$ vs. doxorubicin group; $\&P < 0.05$ vs. hsa-miR-28-5p mimic NC + doxorubicin group.**
in the S-phase compared to the other three groups ($P < 0.05$). Therefore, the intervention with hsa-miR-28-5p mimic + doxorubicin showed a significant decrease in the cell growth and arrest of the cell cycle in the S-phase, eventually blocking the DNA synthesis in tumor cells. Our results indicated that the hsa-miR-28-5p blocked the replication of OCI-LY1 cells and regulated the transitions among the S, subsequent G2/M, and the previous G0/G1 phases. Simultaneously, the cell proportion in the G0/G1 phase in the hsa-miR-28-5p mimic + doxorubicin group was found to be lower than that of the other three groups ($P < 0.05$). The doxorubicin group had a significantly lower ratio of cells in the G2/M phase than the hsa-miR-28-5p mimic + NC group, but it was more than that in the control group ($P < 0.05$). In addition, the cell percentage of the S-phase in the hsa-miR-28-5p NC + doxorubicin group and doxorubicin group was higher when compared with that in the control group, respectively ($P < 0.05$). The percentage of S-phase cells between hsa-miR-28-5p NC + doxorubicin and doxorubicin groups was different ($P < 0.05$). It could be seen that after doxorubicin intervention, OCI-LY1 cell proliferation decreased, the number of cells in the S-phase increased, and cells were arrested in the S-phase. In addition, the overexpression of hsa-miR-28-5p promoted the ability of doxorubicin to regulate the OCI-LY1 cell cycle, which resulted in the arresting of more OCI-LY1 cells in the S-phase, reducing the proliferative activity of tumor cells (Figure 12).

### 4. Discussion

Clinically, the primary manifestation of DLBCL is “painless and swollen lymphadenopathy” that usually occurs in the lymph nodes. However, it can also be found in the gastrointestinal tract, liver, skin, lungs, brain, testicles, uterus, ovaries, and other extra-nodal organs. Often the first reason for such patients to go to the doctor is lymphadenopathy in the neck. DLBCL is highly invasive with a short natural course. The CHOP regimen containing Anthracyclines drugs is the most classical treatment used for DLBCL. Although few patients with DLBCL can be cured with CHOP, more than 50% of patients develop resistance or may relapse, probably due to the presence of DLBCL cells resistant to the CHOP regimen [7]. This may eventually lead to patients’ death due to the tumor, and the changes in the prognosis. However, some patients have still shown the phenomenon of treatment failure, disease progression, or recurrence due to chemotherapeutic resistance.

The difficulty in treating DLBCL is related to the multidiagnostic resistance of cancer cells. Multidrug Resistance (MDR) denotes the cross-resistance of tumor cells to certain chemotherapeutic drugs, which belong to different classes of drugs with different structures and functions. Tumor cells use MDR as a vital mechanism to escape the attack of chemotherapeutic drugs. Hortobágyi pointed out that the phenomenon of MDR and adverse drug reactions have limited the wide application of Anthracyclines [9]. Currently, the development of MDR is mainly related to the expression of MDR protein, DNA damage and repair, the change of Topoisomerase II activity, the characteristics of stem cells obtained from the tumor, and the changes in metabolism [10]. Therefore, studying the mechanism of drug resistance in tumor cells and improving the sensitivity of tumor cells to chemotherapeutic drugs has now become a hot topic and urgent problem.

According to the literature, the mechanism of doxorubicin involves the following three main aspects [11, 12]: (1) Doxorubicin insertion into the adjacent base pairs of DNA, resulting in DNA chain cleavage and blocking of DNA and mRNA synthesis. (2) Doxorubicin inhibition of Topoisomerase II activity, eventually leading to DNA fragmentation. (3) Doxorubicin induction of the production of free radicals, triggering lipid peroxidation. According to Lim [13], the overexpression of hsa-miR-28-5p was associated with the regulation of PD-L1 levels. Therefore, to determine the expression levels of PD-L1 in DLBCL tissues, we selected the tissues from the primary central nervous system of DLBCL (PCNS-DLBCL) patients in our experiment, which is shown in Figures 13(a)–13(f). When the cutoff value of PD-L1 was 10% or 20%, PD-L1 was not found connected to the prognosis of DLBCL patients ($P = 0.087 > 0.05$ or $P = 0.093 > 0.05$), but if the cutoff value was 5%, PD-L1 was found to be associated with a better prognosis of DLBCL patients ($P = 0.043 < 0.05$) (Figures 13–14).

### 3.4. Relationship between PD-L1 and the Prognosis of Patients in Human DLBCL Tissues

The next goal of our research group was to study whether the effect and mechanism of hsa-miR-28-5p in the occurrence and therapeutic effect of DLBCL was through the regulation of PD-L1 levels. Therefore, to determine the expression levels of PD-L1 in DLBCL tissues, we selected the tissues from the primary central nervous system of DLBCL (PCNS-DLBCL) patients in our experiment, which is shown in Figures 13(a)–13(f). When the cutoff value of PD-L1 was 10% or 20%, PD-L1 was not found connected to the prognosis of DLBCL patients ($P = 0.087 > 0.05$ or $P = 0.093 > 0.05$), but if the cutoff value was 5%, PD-L1 was found to be associated with a better prognosis of DLBCL patients ($P = 0.043 < 0.05$) (Figures 13–14).
with a better prognosis of DLBCL. DLBCL displayed a different miRNA expression profile from that of the benign B-cells, which dysregulated the miRNAs’ role in B-cell differentiation and the creation of the lymphocyte. Doxorubicin affected the proliferation, apoptosis, and cell cycle of breast cancer cells [14]. Hence, to improve the efficacy of the current R-CHOP regimen in DLBCL patients, we focused on studying the effect of hsa-miR-28-5p on doxorubicin sensitivity in DLBCL cells.

Our results suggested that the optimal concentration of doxorubicin to treat DLBCL cells was 3.028 μmol/l. At this concentration, the apoptosis of DLBCL cells was enhanced by doxorubicin, and also the DLBCL cells were less resistant to doxorubicin. Doxorubicin is a highly effective chemotherapeutic agent which belongs to the group Anthracyclines. It is also a specific inhibitor of Topoisomerase II, which can inhibit DNA and RNA synthesis. Considered to be one of the most effective chemotherapeutic drugs, doxorubicin is the most widely used Anthracycline drug leading to cytotoxic death of tumor cells. It also exhibits significant chemotherapeutic activity in lymphoma, breast cancer, acute leukemia, and so on [15]. However, the emergence of doxorubicin resistance has limited its application in clinical treatment. Several studies have shown that drug resistance in tumor cells may be associated with miRNAs [16]. miRNAs are speculated to regulate about one-third of human genes. The miRNA regulation in gene expression is an independent feature that distinguishes it from other RNAs, making it a new tumor biomarker and potential therapeutic target [17]. Besides the influence of pharmacological mechanisms, drug resistance in tumors is also related to the abnormal regulation of miRNA on target genes in diseases such as lung cancer, liver cancer, colorectal cancer, and breast cancer [18–21]. Numerous miRNAs are recognized as biomarkers for B-cell lymphoma, with their aberrant levels tightly associated with the disease’s occurrence [22, 23].

![Figure 11](image-url)

**Figure 11**: Effects of the combination of hsa-miR-28-5p and doxorubicin on the apoptosis of OCI-LY1 cells. (a) Flow cytometry detection of apoptosis; (b) statistical analysis graph; (c) the expression of apoptosis-related proteins detected by WB. *P < 0.05 vs. control group; #P < 0.05 vs. doxorubicin group; &P < 0.05 vs. hsa-miR-28-5p mimic NC + doxorubicin group.
Figure 12: Effects of the combination of hsa-miR-28-5p and doxorubicin on the cell cycle of OCI-LY1 cells.

Figure 13: Immunohistochemical results of DLBCL tissues (diffuse large B-cell lymphoma) (EnVision method, original magnification 200x). (a) Negative control; (b) PD-L1-negative oncocytes; (c) positive control: PD-L1 expression in placental tissue; (d) PD-L1 weak positive expression in oncocytes; (e) PD-L1 moderate positive expression in oncocytes; (f) PD-L1 strong positive expression in oncocytes.
miRNAs are also found tightly related to the genesis and progression of DLBCL [24]. Studies have reported that miR-34a, miR-99a-5p, miR-125b-5p, miR-155, miR-370-3p, miR-381-3p, and miR-409-3p are abnormally expressed in DLBCL disease [24–27]. miRNAs are a therapeutic target that can add the sensitivity of DLBCL cells to chemotherapy. They are also associated with chemosensitivity in a variety of malignant tumors, including DLBCL [28, 29]. In 2019, Amri identified miR-125a-5p to be a potential therapeutic adjuvant for lung cancer [18]. Overexpression of miR-185 can lead to shorter survival by improving TKI sensitivity in TKI nonresponder stem/progenitor cells [28].

Up-regulation of miR-185 expression is reported to increase the radiosensitivity of colorectal cancer cells [30]. Therefore, it is urgent to study the effect of miRNA inhibitors or miRNA mimics on chemotherapeutic drugs to develop them as auxiliary means of chemotherapy. The above-mentioned studies not only showed the potential clinical value of miRNA as a novel biomarker and therapeutic drug, but they also highlighted the value of miRNA in clinical applications along with their potential in predicting the drug response and applications in treatment.

miR-28, a miRNA, is located within the gene on chromosome 3q28. It is a tumor suppressor and a viral suppressor [31] gene, which is regulated through the binding of STAT3 and p53 to its promoter [32]. In humans, the miR-28 family is divided into subtypes miR-28-3p and miR-28-5p, named after the 3′ and 5′ ends of the pre-miR-28, respectively. These subtypes display biological differences in stability and functionality [33]. Both hsa-miR-28-3p and hsa-miR-28-5p can target several tumor-related genes involved in cell proliferation, migration, invasion, and EMT [34]. The miR-28-5p was reported to be significantly down-regulated in hepatocellular carcinoma [35], colorectal cancer [36], and multiple myeloma [37]. Additionally, miR-28-5p hindered gastric cancer (GC) cell invasion and migration by suppressing NRF2 [38]. It also inhibited the proliferation of nasopharyngeal carcinoma cells in vitro, thus, inducing apoptosis and cell cycle arrest [33]. Moreover, miR-28-5p induced apoptosis of chronic lymphocyte leukemia cells [39] and hindered the proliferation and migration of glioma cells by targeting Rap1b and interfering with genes involved in cell replication and cell cycle checkpoint [40], whose results were consistent with our previous research [3]. Additionally, miR-28-5p inhibited cell proliferation and migration in Renal Cell Carcinoma by directly inhibiting the Rap1b gene [41]. The miR-28-5p was also reported to inhibit cell growth and promote apoptosis of DLBCL cells through Curcumin [42].

Studies have also found that miR-28-5p was upregulated in some tumors, implying their critical role in tumor metastasis and invasion [43]. Besides, the miR-28-5p induced the arrest of ovarian cancer cells in the S-phase by down-regulating N4BP1 along with promoting their proliferation and invasion [43]. A study suggested that miR-28-5p suppressed the cell growth, invasion, and migration of NSCLC by targeting HIF-1α and inducing apoptosis in lung cancer cells [44].

The miR-197 mimic can enhance the chemosensitivity of lung cancer cells by increasing the PD-L1 expression [29]. The miRNAs can promote the efficacy of NSCLC by modulating PD-L1 levels and other molecules involved in cell proliferation [45, 46]. In the current work, we found that positive expression of PD-L1 in DLBCL tissues was related to a good prognosis of DLBCL patients at the cutoff value of 5%, which was similar to a related study [47]. However, it was inconsistent with some other studies [48]. Our research group aims to explore the expression levels of PD-L1 in DLBCL cells and also the mechanism underlying the effect of hsa-miR-28-5p on the development and therapeutic effect of DLBCL through the regulation of PD-L1 expression.

5. Conclusion

In summary, the combination of hsa-miR-28-5p and doxorubicin is more effective than doxorubicin alone in inhibiting cell proliferation, promoting apoptosis, and blocking the cell cycle of DLBCL cells. Also, the effects of
doxorubicin on DLBCL cells were found to be time- and concentration-dependent. Overexpression of hsa-miR-28-5p enhances the therapeutic effect of doxorubicin on DLBCL cells, which may be attributed to its role in modulating the PD-L1 levels. Our findings may provide a new treatment method to reduce the multidrug resistance in DLBCL cells, laying a foundation for the next step of future research.

Data Availability

All data generated or analyzed during this study are included in this published article.

Ethical Approval

This study was approved by the Medical Ethics Committee of The Tumor Hospital Affiliated to Xinjiang Medical University (20160218-13) and the Medical Ethics Committee of Karamay Central Hospital (YL-2021-18) (YL-2021-8).

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

SFY and XXL conceived and designed the study. QYS, HPZ, BL, HLG, MF, KC, and LXG performed the study and analyzed the data. SFY wrote the paper. All authors contributed equally to the manuscript. All authors read and approved the final version of the manuscript.

Acknowledgments

This research was funded by the Science and Technology Talents of Science and Technology Foundation of Xinjiang Uygur Autonomous Region (no. WJWY-202215), the Natural Science Foundation of Xinjiang Uygur Autonomous Region (no. 2021D01A26), Special Program for Young Medical Talent of the National Natural Science Foundation of China (no. 81660036), and the Cisco-Roche Solid Tumor Research Foundation (no. Y-roche 2019/2-0061).

References

[1] S. H. Swerdlow, E. Campo, N. L. Harris et al., *WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues*, International Agency for Research on Cancer, Lyon, France, 4th Edition, 2017.

[2] E. V. D. Neste, N. Schmitz, N. Mounier et al., “Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study,” *Bone Marrow Transplantation*, vol. 52, no. 2, pp. 216–221, 2017.

[3] S. Yan, Y. Chen, M. Yang et al., “hsa-MicroRNA-28-5p inhibits diffuse large B-cell lymphoma cell proliferation by downregulating 14-3-3ζ expression,” *Evidence-based Complementary and Alternative Medicine*, vol. 2022, pp. 1–13, Article ID 4605329, 2022.

[4] J. S. Weber, R. R. Kuchachdar, B. Yu et al., “Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or-naïve melanoma,” *Journal of Clinical Oncology*, vol. 31, no. 34, pp. 4311–4318, 2013.

[5] D. P. Carbone, M. Reck, L. Paz-Ares et al., “First-line nivolumab in stage IV or recurrent non–small-cell lung cancer,” *New England Journal of Medicine*, vol. 376, no. 25, pp. 2415–2426, 2017.

[6] S. Huang, L. Nong, W. Wang et al., “Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma,” *Diagnostic Pathology*, vol. 14, no. 1, p. 81, 2019.

[7] R. I. Fisher, E. R. Gaynor, S. Dhalberg et al., “Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-hodgkin’s lymphoma.” *New England Journal of Medicine*, vol. 328, no. 14, pp. 1002–1006, 1993.

[8] M. A. Shipp, K. N. Ross, P. Tamayo et al., “Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning,” *Nature Medicine*, vol. 8, no. 1, pp. 68–74, 2002.

[9] G. N. Hortobágyi, "Anthracyclines in the treatment of cancer. an overview," *Drugs*, vol. 54, pp. 1–7, 1997.

[10] T. Capelóa, Z. Benyahia, L. X. Zampieri, M. C. Blackman, and P. Sonveaux, “Metabolic and non-metabolic pathways that control cancer resistance to anthracyclines,” Seminars in Cell & Developmental Biology, vol. 98, pp. 181–191, 2020.

[11] B. Kalyanaraman, J. Joseph, S. Kalivendi, S. Wang, E. Konorev, and S. Komatramu, “Doxorubicin-induced apoptosis: implications in cardiotoxicity,” *Molecular and Cellular Biochemistry*, vol. 234/235, no. 1, pp. 119–124, 2002.

[12] G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni, “Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity,” Pharmacological Reviews, vol. 56, no. 2, pp. 185–229, 2004.

[13] E. L. Lim, D. L. Trinh, D. W. Scott et al., “Comprehensive miRNA sequence analysis reveals survival differences in diffuse large B-cell lymphoma patients,” *Genome Biology*, vol. 16, no. 1, p. 18, 2015.

[14] J. L. Granados-Soler, J. Junginger, M. Hewicker-Trautwein et al., “TlHo-0906: a new feline mammary cancer cell line with molecular, morphological, and immunocytological characteristics of epithelial to mesenchymal transition,” *Scientific Reports*, vol. 8, no. 1, Article ID 13231, 2018.

[15] D. G. DeNardo, D. J. Brennan, E. Reixhepa et al., “Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy,” *Cancer Discovery*, vol. 1, no. 1, pp. 54–67, 2011.

[16] C. Y. Ting, S. M. Liew, A. Price et al., “Clinical significance of aberrant microRNAs expression in predicting disease relapse/ refractoriness to treatment in diffuse large B-cell lymphoma: a meta-analysis,” *Critical Reviews in Oncology*, vol. 144, Article ID 102818, 2019.

[17] L. Y. Wang, F. L. Xue, X. S. Shi, and J. F. Shen, “The mechanism and potential clinical significance of miRNA in lung cancer,” *Chinese Journal of Thoracic Surgery*, vol. 8, no. 1, pp. 40–50, 2021.

[18] J. Amri, N. Molaee, and H. Karami, “Up-regulation of MiRNA-125a-5p inhibits cell proliferation and increases EGFR-TKI induced apoptosis in lung cancer cells,” *Asian Pacific Journal of Cancer Prevention*, vol. 20, no. 11, pp. 3361–3367, 2019.
antitumour treatments (review)," International Journal of Molecular Medicine, vol. 41, no. 4, pp. 1809–1816, 2018.
[20] Y. Chen, B. Zhang, Y. Jin, Q. Wu, and L. Cao, "MiR-27b targets PI3K p110α to inhibit proliferation and migration in colorectal cancer stem cell," American Journal of Translational Research, vol. 11, no. 9, pp. 5998–5997, 2019.
[21] D. Chen, W. Si, J. Shen et al., "miR-27b-3p inhibits proliferation and potentially reverses multi-chemoresistance by targeting CBLB/GRB2 in breast cancer cells," Cell Death & Disease, vol. 9, no. 2, p. 188, 2018.
[22] M. Lopez-Santillan, A. Larrabeti-Etxebarria, J. Arzuaga-Mendez, E. Lopez-Perez, and A. Garcia-Orad, "Circulating miRNAs as biomarkers in diffuse large B-cell lymphoma: a systematic review," Oncotarget, vol. 9, no. 32, pp. 22850–22861, 2018.
[23] C. Solé, E. Arnaiz, and C. H. Lawrie, "MicroRNAs as biomarkers of B-cell lymphoma," Biomarker Insights, vol. 13, 2018.
[24] Y. Feng, M. Zhong, S. Zeng et al., "Exosome-derived miRNAs as predictive biomarkers for diffuse large B-cell lymphoma chemotherapy resistance," Epigenomics, vol. 11, no. 1, pp. 35–51, 2019.
[25] S. K. Leivonen, K. Icay, K. Jäntti et al., "MicroRNAs regulate key cell survival pathways and mediate chemosensitivity during progression of diffuse large B-cell lymphoma," Blood Cancer Journal, vol. 7, no. 12, p. 654, 2017.
[26] S. C. Marques, B. Ranjarb, M. B. Laursen et al., "High miR-34a expression improves response to doxorubicin in diffuse large B-cell lymphoma," Experimental Hematology, vol. 44, no. 4, pp. 238.e2–246.e2, 2016.
[27] N. Zare, S. Haghighi Javanmard, V. Mehrzad, N. Eskandari, and A. Kefayi, "Evaluation of exosomal miR-155, let-7g and let-7i levels as a potential noninvasive biomarker among refractory/relapsed patients, responsive patients and patients receiving R-CHOP," Leukemia and Lymphoma, vol. 60, no. 8, pp. 1877–1889, 2019.
[28] H. Lin, K. Rothe, M. Chen et al., "The miR-185-PAK6 axis predicts therapy response and regulates survival of drug-resistant leukemic stem cells in CML," Blood, vol. 136, no. 5, pp. 596–609, 2020.
[29] Y. Fujita, S. Yagishita, K. Hagiwara et al., "The clinical relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 network in chemoresistant non-small-cell lung cancer," Molecular Therapy, vol. 23, no. 4, pp. 717–727, 2015.
[30] S. Afshar, R. Najafi, A. Sedighi Pashaki et al., "MiR-185 enhances radiosensitivity of colorectal cancer cells by targeting IGF1R and IGF2," Biomedicine & Pharmacotherapy, vol. 106, pp. 763–769, 2018.
[31] J. Yu, Q. Xu, X. Zhang, and M. Zhu, "Circulating microRNA signatures serve as potential diagnostic biomarkers for Helicobacter pylori infection," Journal of Cellular Biochemistry, vol. 120, 2018.
[32] K. Skrzypek, A. Nieszporek, B. Badyra, M. Lasota, and M. Majka, "Enhancement of myogenic differentiation and inhibition of rhabdomyosarcoma progression by miR-28-3p and miR-193a-5p regulated by SNAIL," Molecular Therapy-Nucleic Acids, vol. 24, pp. 888–904, 2021.
[33] Y. Lv, H. Yang, X. Ma, and G. Wu, "Strand-specific miR-28-3p and miR-28-5p have differential effects on nasopharyngeal cancer cells proliferation, apoptosis, migration and invasion," Cancer Cell International, vol. 19, no. 1, p. 187, 2019.
[34] J. Xu, N. Jiang, H. Shi, S. Zhao, S. Yao, and H. Shen, "miR-28-5p promotes the development and progression of ovarian cancer through inhibition of N4BP1," International Journal of Oncology, vol. 50, no. 4, pp. 1383–1391, 2017.
[35] S. L. Zhou, Z. Q. Hu, Z. J. Zhou et al., "miR-28-5p-IL-34 macrophage feedback loop modulates hepatocellular carcinoma metastasis," Hepatology, vol. 63, no. 5, pp. 1560–1575, 2016.
[36] W. Wu, K. He, Q. Guo et al., "SSRP1 promotes colorectal cancer progression and is negatively regulated by miR-28-5p," Journal of Cellular and Molecular Medicine, vol. 23, no. 5, pp. 3118–3129, 2019.
[37] Z. Li, K. Y. Wong, G. C. F. Chan, and C. S. Chim, "Epigenetic silencing of LPP/miR-28 in multiple myeloma," Journal of Clinical Pathology, vol. 71, no. 3, pp. 253–258, 2018.
[38] C. F. Yue, L. S. Li, L. Ai, J. K. Deng, and Y. M. Guo, "miCroRNA-28-5p acts as a metastasis suppressor in gastric cancer by targeting Nrf2," Experimental Cell Research, vol. 402, no. 2, Article ID 112553, 2021.
[39] Y. Q. Yang, T. Tian, H. Y. Zhu et al., "NDRG2 mRNA levels and miR-28-5p and miR-650 activity in chronic lymphocytic leukemia," BMC Cancer, vol. 18, no. 1, Article ID 1009, 2018.
[40] J. Wan, A. A. Guo, I. Chowdhury et al., "TRPM7 induces mechanistic target of Rap1b through the downregulation of miR-28-5p in glioma proliferation and invasion," Frontiers Oncology, vol. 9, Article ID 1413, 2019.
[41] C. Wang, C. Wu, Q. Yang et al., "miR-28-5p acts as a tumor suppressor in renal cell carcinoma for multiple antitumor effects by targeting RAPIB," Oncotarget, vol. 7, no. 45, pp. 73888–73902, 2016.
[42] T. Kang, W. L. Sun, X. F. Lu, X. L. Wang, and L. Jiang, "MiR-28-5p mediates the anti-proliferative and pro-apoptotic effects of curcumin on human diffuse large B-cell lymphoma cells," Journal of International Medical Research, vol. 48, no. 7, Article ID 03000652049379, 2020.
[43] Q. Han, J. Li, J. Xiong, and Z. Song, "Long noncoding RNA LINC00514 accelerates pancreatic cancer progression by acting as a ceRNA of miR-28-5p to upregulate Rap1b expression," Journal of Experimental & Clinical Cancer Research, vol. 39, no. 1, p. 151, 2020.
[44] X. Ma, C. Wang, J. Chen, D. Wei, F. Yu, and J. Sun, "circAGFG1 sponges miR-28-5p to promote non-small-cell lung cancer progression through modulating HIF-1α level," Open Medicine, vol. 16, no. 1, pp. 703–717, 2021.
[45] N. Andratschke, J. Kraft, C. Nieder et al., "Optimal management of brain metastases in oncogenic-driven non-small cell lung cancer (NSCLC)," Lung Cancer, vol. 129, pp. 63–71, 2019.
[46] C. Raimondi, G. Carpino, C. Nicolazzo et al., "PD-L1 and epithelial-mesenchymal transition in circulating tumor cells from non-small cell lung cancer patients: a molecular shield to evade immune system?" Oncoimmunology, vol. 6, no. 12, Article ID e1315488, 2017.
[47] R. McCord, C. R. Bolen, H. Koeppen et al., "PD-L1 and tumor-associated macrophages in de novo DLBCL," Blood Advances, vol. 3, no. 4, pp. 531–540, 2019.
[48] S. Kim, S. J. Nam, C. Park et al., "High tumoral PD-L1 expression and low PD-1 + or CD8 + tumor-infiltrating lymphocytes are predictive of a poor prognosis in primary diffuse large B-cell lymphoma of the central nervous system," Oncoimmunology, vol. 8, no. 9, Article ID e1626653, 2019.